Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800979 | 0.77 | ATM (0.39) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL1185401 | 0.72 | ATM (0.54) | ATMAAK1TACR1SYKCTSK | |
| SCHEMBL7324987 | 0.72 | ATM (0.54) | ATMAAK1TACR1SYKCTSK | |
| SCHEMBL12299153 | 0.71 | CTSL (0.45) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL23006720 | 0.71 | CTRB1 (0.57) | ATMSYKCTSKCTSLCTSB | |
| SCHEMBL800463 | 0.70 | MAPT (0.44) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL7421358 | 0.67 | FPR2 (0.51) | ATMAAK1TACR1SYKCTSK | |
| SCHEMBL265512 | 0.67 | CTSK (0.64) | TACR1SYKCTSKCTSLCTSB | |
| SCHEMBL8896054 | 0.67 | SYK (0.55) | ATMSYKCTSKCTSLCTSB | |
| SCHEMBL2895983 | 0.67 | CTSK (0.64) | TACR1SYKCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | ATM 1276/4885AAK1 3541/4885TACR1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.